Abstract
The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Current Molecular Medicine
Title: RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Volume: 11 Issue: 8
Author(s): K. J. Doherty, C. McKay, K. K. Chan and M. K. El-Tanani
Affiliation:
Keywords: Ran GTPase, Ranbp1, Ranbp2, Ranbp9, Ranbp10, c-met, nucleo-cytoplasmic transport, macromolecules, anthologies, mitosis, cancer, oncogenic pathway, metastasis, microtubule-interacting drugs, chemotherapy
Abstract: The identification of a relevant effector of Ran GTPase (Ran) signaling and its pathways could provide a novel approach to cancer therapeutics. With recent research highlighting the significant relationship between Ran expression and the occurrence and progression of cancer, the development of a small molecule compound that would decrease the endogenous levels of Ran in the cell would have anti-mitotic effects and could lead to the development of new types of cancer therapeutics. In the absence of Ran binding proteins, Ran is expected to remain locked up in non-productive complexes with importins and is effectively removed from the system. Thus, Ran binding proteins present as a logical molecular target for the inhibition of Ran signaling within the cancer cell. Moreover, this family of proteins has been shown to have various other functions within the cell, some of which are also anti-neoplastic. The purpose of this review is to discuss Ran binding proteins and how their pathways may be exploited to provide an effective cancer treatment.
Export Options
About this article
Cite this article as:
J. Doherty K., McKay C., K. Chan K. and K. El-Tanani M., RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins, Current Molecular Medicine 2011; 11 (8) . https://dx.doi.org/10.2174/156652411797536688
DOI https://dx.doi.org/10.2174/156652411797536688 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gambogic Acid is a Novel Anti-cancer Agent that Inhibits Cell Proliferation, Angiogenesis and Metastasis
Anti-Cancer Agents in Medicinal Chemistry Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
Current Medicinal Chemistry Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies
Current Pharmaceutical Biotechnology Adjuvant Zoledronic Acid Reduces Disease Recurrence in Breast Cancer: Antitumor Effects on the Seed and the Soil
Current Cancer Therapy Reviews Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
Current Medicinal Chemistry Profiling of Multiple Signal Pathway Activities by Multiplexing Antibody and GFP-Based Translocation Assays
Combinatorial Chemistry & High Throughput Screening A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Targeting the Ataxia Telangiectasia Mutated Protein in Cancer Therapy
Current Drug Targets Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Exploiting APC Function as a Novel Cancer Therapy
Current Drug Targets HSF1 as a Cancer Biomarker and Therapeutic Target
Current Cancer Drug Targets TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
Current Medicinal Chemistry Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Novel Drugs for Neuroblastoma
Drug Design Reviews - Online (Discontinued) Multifaceted Role of Neuropilins in Cancer
Current Medicinal Chemistry